Why the study?
The dorsomedial periaqueductal gray regulates cardiovascular functions and is affected by inflammation, and lipopolysaccharide affects blood pressure, motivating investigation of the cardiovascular effects of lipopolysaccharide microinjection into this region.
Microinjection of LPS into the dmPAG in rats induces a significant hypotensive response, highlighting a potential central mechanism for inflammation-mediated cardiovascular changes.
LPS microinjection into rat dmPAG alters cardiovascular responses; leaves open any role in human inflammatory states.
The dorsomedial periaqueductal gray (dmPAG) is located around the cerebral aqueduct with various functions such as cardiovascular regulation and is affected by inflammation. Lipopolysaccharide (LPS) is a complex molecule with an inflammatory effect that is known to affect blood pressure. In the present study, the cardiovascular effect of LPS microinjection into the dmPAG was investigated. Methods: Rats were divided into three groups consisting of 1: control; 2: 50 ng LPS and 3: 100 ng LPS. Rats were mounted on a stereotaxic device after anesthesia and a continuous recording of cardiovascular parameters was done by a PowerLab device, connected to a cannulated femoral artery and drugs microinjected into dmPAG. The changes () in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and heart rate (HR) were calculated at different times and compared to the control group. Results: Both doses of LPS when microinjected into the dmPAG brought on a significant hypotensive response in the pressure parameters (MAP, SBP, and DBP) when compared to control. A non-significant increase in HR was also documented in both groups.
No takes yet. Share an insight, caveat, or question.
Mohebbati et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: